Webinar for the CIBRN community presented by all CIBRN Leaders Thurs, June 8, 9:00 pm EST

Please join the CIBRN Leaders for an in-depth, cross-discipline discussion of CIBRN 2017 Question #1, Question #2 & Question #3 surrounding the implications of the evolving biosimilar landscape on clinical practice and patient health in Canada.

This webinar is intended for the ALL CIBRN members and is scheduled for Thursday, June 8th, 9:00-10:00 pm ESTWebinar connection details will follow by email.

Prior to the webinar, you are invited to visit the CIBRN community on Sosido to review the questions & responses and to reply with your personal clinical perspectives:

The webinar will be recorded and archived for future viewing by the CIBRN community.

If you have any comments or questions, please contact me at your convenience.

Paul Abbass
LEGITIMED INC.
Email: paul.abbass@legitimed.com

—————-

If you have never attended an Adobe Connect meeting before:

Test your connection: https://studio7communications.adobeconnect.com/common/help/en/support/meeting_test.htm

Get a quick overview: http://www.adobe.com/products/adobeconnect.html

AGA Makes Six Recommendations to FDA on Interchangeable Biosimilars

Source: American Gastroenterological Association, May 25 2017

http://www.gastro.org/news_items/aga-makes-six-recommendations-to-fda-on-interchangeable-biosimilars/?

Gastroenterologists and patients rely on biologics to manage Crohn’s disease and ulcerative colitis. Biosimilar products, which are “highly similar” to the biologic, have begun to be approved by the FDA for such indications. The FDA is now developing a pathway for interchangeable products, which are biosimilars that “may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product” according to Section 351(i) of the Public Health Service Act. Last week, AGA provided the FDA six recommendations in response to the agency’s draft guidance on demonstrating interchangeability focused on measures to enhance patient safety and ensure that physicians, not insurance companies, drive decisions about switching products. Here is a summary of our comments … [view full article]

View a Summary of the 2016 CIBRN Learning Program: Video Learning MicroModule Now Available Online

As we get ready to kick off our second year of the CIBRN learning program, we invite you to review the CIBRN micromodule video from the 2016 season. The video is under 20 minutes in length and will provide an overview of discussions surrounding structured questions authored by CIBRN Leaders.

Watch the 2016 CIBRN micromodules here:

English: http://studio7web.ca/clients/Legitimed/CIBRN_BiosimilarSummary_2016/English/

Français: http://studio7web.ca/clients/Legitimed/CIBRN_BiosimilarSummary_2016/French/